Use of the nav1.6 sodium channel blocker (s)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-n(thiazol-4-yl)benzenesulfonamide, together with strong inducers of cytochrome p450 3a4, in the treatment of conditions associated with navi.6 activity

A method of treating epilepsy in a patient wherein the patient is also being administered a therapeutically effective amount of phenytoin, the method comprising:

• administering to the patient in need thereof a therapeutically effective amount of (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzenesulfonamide (Compound A), or a pharmaceutically acceptable salt thereof.

A method of treating a disease or a condition associated with Nav1.6 activity in a patient, the method comprising:

• administering to the patient in need thereof a therapeutically effective amount of (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzenesulfonamide (Compound A), or a pharmaceutically acceptable salt thereof,
• subsequently determining that the patient is to begin treatment with a strong inducer of cytochrome P450 3A4 (CYP3A4), and
• continuing administration of Compound A, or a pharmaceutically acceptable salt thereof, to the patient.

A method of treating a disease or a condition associated with Nav1.6 activity in a patient wherein the patient is also being administered a strong inducer of cytochrome P450 3A4 (CYP3A4), the method comprising:

• administering to the patient in need thereof a therapeutically effective amount of (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzenesulfonamide (Compound A), or a pharmaceutically acceptable salt thereof,
• wherein the administration produces a median time to peak plasma concentrations (Tmax) for Compound A, or a pharmaceutically acceptable salt thereof, that is about the same for a patient who is not being administered a strong inducer of CYP3A4 than the median Tmax for Compound A, or a pharmaceutically acceptable salt thereof, for a patient who is not being administered a strong inducer of CYP3A4.

A method of treating a disease or a condition associated with Nav1.6 activity in a patient wherein the patient is also being administered a strong inducer of cytochrome P450 3A4 (CYP3A4), the method comprising:

• administering to the patient in need thereof a therapeutically effective amount of (S)-4-((1-benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzenesulfonamide (Compound A), or a pharmaceutically acceptable salt thereof,
• wherein the administration an area under the curve from time 0 to the last sampling time point (AUC0-t) and to infinity (AUC0-inf) for Compound A, or a pharmaceutically acceptable salt thereof, that is about the same for a patient who is not being administered a strong inducer of CYP3A4, than the administration an AUC0-t and to AUC0-inf for Compound A, or a pharmaceutically acceptable salt thereof, for a patient who is not being administered a strong inducer of CYP3A4.